ALIVUS Share Price Performance
₹900.65
-112.65 (-11.12%)
30.6% undervalued intrinsic discount
₹1,297.33
Fair Value
Price ₹900.65
AnalystConsensusTarget ₹1,297.33
Fair Value₹1,297.33
Share Pricen/a
Alivus Life Sciences Limited Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 12 Fair Values set on narratives written by author
ALIVUS Community Narratives
AN
Fair Value ₹1.3k 30.6% undervalued intrinsic discount
Capacity Expansion And Complex APIs Will Drive Long Term Earnings Power
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
Capacity Expansion And Complex APIs Will Drive Long Term Earnings Power
Catalysts About Alivus Life Sciences Alivus Life Sciences is a specialty pharmaceutical ingredients and CDMO company focused on complex, high value APIs and partnered development for global regulated markets. What are the underlying business or industry changes driving this perspective?Read more
10
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
AN
₹1.3k
30.6% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
11.17% p.a.
Profit Margin
0.27%
Future PE
24.55x
Price in 2028
₹18.6
Trending Discussion
Recently Updated Narratives
AN
Capacity Expansion And Complex APIs Will Drive Long Term Earnings Power
Fair Value: ₹1.3k 30.6% undervalued intrinsic discount
2 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Alivus Life Sciences Limited Key Details
About ALIVUS
- Founded
- 2001
- Employees
- 2203
- CEO
- WebsiteView website
Alivus Life Sciences Limited develops, manufactures, and markets active pharmaceutical ingredients in India, Japan, Europe, North and Latin America, and internationally. It offers various APIs, such as olmesartan, telmisartan, solifenacin, sitagliptin, zonisamide, rosuvastatin, amiodarone, ezetimibe, lithium carbonate, oxcarbazepine, mirabegron, atovaquone, etoricoxib, remogliflozin, cabozantinib, and palbociclib for various therapeutic areas, including cardiovascular disease, central nervous system disorders, diabetes, gastrointestinal health, oncology, pain management, immunosuppressant, respiratory and ophthalmologic agents, urology, and anti-infectives. The company also provides contract development and manufacturing services to a range of multinational corporations and specialty companies. It exports its products. The company was formerly known as Glenmark Life Sciences Limited and changed its name to Alivus Life Sciences Limited in December 2024. The company was founded in 2001 and is based in Mumbai, India. Alivus Life Sciences Limited is a subsidiary of Nirma Limited.
